Silja Chouquet examines the Twitter noise at pharma meetings and offers pointers to keep KOLs engaged while avoiding the attention of worthless click-farm accounts.
In its bid to satisfy investors with returns on paid advertising, Twitter is damaging genuine engagement, while pharma's buying power is quoshing the opportunity for balanced conversations, say
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh